TY - JOUR
T1 - 67/68Galmydar
T2 - A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity
AU - Sivapackiam, Jothilingam
AU - Harpstrite, Scott E.
AU - Prior, Julie L.
AU - Mattingly, Stephen
AU - Sharma, Vijay
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Introduction: For stratification of chemotherapeutic choices, radiopharmaceuticals capable of imaging breast cancer resistance protein (BCRP/ABCG2)-mediated functional transport are desired. To accomplish this objective, Galmydar, a fluorescent and moderately hydrophobic Ga(III) cationic complex and its 67/68Ga-radiolabeled counterparts were interrogated in HEK293 cells stably transfected with BCRP and their WT counterparts transfected with empty vector. Additionally, the sensitivity and specificity of 68Ga-Galmydar to evaluate functional expression of BCRP at the blood-brain barrier (BBB) was investigated in gene-knockout mdr1a/1b(-/-) (double knockout, dKO) and mdr1a/1b(-/-)ABCG2(-/-) (triple knockout, tKO) mouse models. Methods: For radiotracer uptake assays and live cell fluorescence imaging, either 67Ga-Galmydar or its unlabeled counterpart was incubated in HEK293 cells transfected with BCRP (HEK293/BCRP) and their WT counterparts at 37 °C under a continuous flux of CO2 (5%) in the presence or absence of Ko143, a potent BCRP antagonist, and cellular uptake was measured to assess the sensitivity of Galmydar to probe BCRP-mediated functional transport activity in cellulo. For assessing the potential of Galmydar to enable diagnostic imaging of targeted tissues in vivo, the 67Ga-radiolabeled counterpart was incubated in either human serum albumin or human serum at 37 °C and the percentage of unbound 67Ga-Galmydar was determined. To evaluate the sensitivity of 68Ga-Galmydar for molecular imaging of BCRP-mediated efflux activity in vivo, microPET/CT brain imaging was performed in dKO and tKO mice and their age-matched WT counterparts, 60 min post-intravenous injection. Results: 67Ga-Galmydar shows uptake profiles in HEK293 cells inversely proportional to BCRP expression, and antagonist (Ko143) induced accumulation in HEK293/BCRP cells, thus indicating target sensitivity and specificity. Furthermore, employing the fluorescent characteristics of Galmydar, optical imaging in HEK293/BCRP cells shows an excellent correlation with the radiotracer cellular accumulation data. 67Ga-Galmydar shows > 85% unbound fraction and presence of parental compound in human serum. Finally, microPET/CT imaging shows higher retention of 68Ga-Galmydar in brains of dKO and tKO mice compared to their age-matched WT counterparts, 60 min post-intravenous tail-vein injection. Conclusions: Combined data indicate that Galmydar could provide a template scaffold for development of a PET tracer for imaging BCRP-mediated functional transport activity in vivo.
AB - Introduction: For stratification of chemotherapeutic choices, radiopharmaceuticals capable of imaging breast cancer resistance protein (BCRP/ABCG2)-mediated functional transport are desired. To accomplish this objective, Galmydar, a fluorescent and moderately hydrophobic Ga(III) cationic complex and its 67/68Ga-radiolabeled counterparts were interrogated in HEK293 cells stably transfected with BCRP and their WT counterparts transfected with empty vector. Additionally, the sensitivity and specificity of 68Ga-Galmydar to evaluate functional expression of BCRP at the blood-brain barrier (BBB) was investigated in gene-knockout mdr1a/1b(-/-) (double knockout, dKO) and mdr1a/1b(-/-)ABCG2(-/-) (triple knockout, tKO) mouse models. Methods: For radiotracer uptake assays and live cell fluorescence imaging, either 67Ga-Galmydar or its unlabeled counterpart was incubated in HEK293 cells transfected with BCRP (HEK293/BCRP) and their WT counterparts at 37 °C under a continuous flux of CO2 (5%) in the presence or absence of Ko143, a potent BCRP antagonist, and cellular uptake was measured to assess the sensitivity of Galmydar to probe BCRP-mediated functional transport activity in cellulo. For assessing the potential of Galmydar to enable diagnostic imaging of targeted tissues in vivo, the 67Ga-radiolabeled counterpart was incubated in either human serum albumin or human serum at 37 °C and the percentage of unbound 67Ga-Galmydar was determined. To evaluate the sensitivity of 68Ga-Galmydar for molecular imaging of BCRP-mediated efflux activity in vivo, microPET/CT brain imaging was performed in dKO and tKO mice and their age-matched WT counterparts, 60 min post-intravenous injection. Results: 67Ga-Galmydar shows uptake profiles in HEK293 cells inversely proportional to BCRP expression, and antagonist (Ko143) induced accumulation in HEK293/BCRP cells, thus indicating target sensitivity and specificity. Furthermore, employing the fluorescent characteristics of Galmydar, optical imaging in HEK293/BCRP cells shows an excellent correlation with the radiotracer cellular accumulation data. 67Ga-Galmydar shows > 85% unbound fraction and presence of parental compound in human serum. Finally, microPET/CT imaging shows higher retention of 68Ga-Galmydar in brains of dKO and tKO mice compared to their age-matched WT counterparts, 60 min post-intravenous tail-vein injection. Conclusions: Combined data indicate that Galmydar could provide a template scaffold for development of a PET tracer for imaging BCRP-mediated functional transport activity in vivo.
KW - BCRP
KW - Gallium
KW - Metalloprobe
UR - http://www.scopus.com/inward/record.url?scp=84975677600&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2015.12.001
DO - 10.1016/j.nucmedbio.2015.12.001
M3 - Article
C2 - 26924499
AN - SCOPUS:84975677600
SN - 0969-8051
VL - 43
SP - 191
EP - 197
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 3
ER -